Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Autoinoculation is suggested as an adjuvant means to augment the effect of surgery in gastric cancer which may prevent the development of recurrences and metastases. Surgery alone is not a curative method and 5-year survival in gastric cancer stage III ranges from 9.2 to 28%. The data have been obtained on comparative survival in a control group and a group of inoculated patients. The greatest effect was achieved in patients with poorly differentiated adenocarcinoma. Further investigation of the two groups adjusted for the patients' age, kind of surgery and morphological structure of the tumor will help to work out precise criteria for inoculation.
...
PMID:[Combined treatment of cancer of the stomach using a specific immunotherapy]. 176 56

This study was conducted in patients with stage III gastric cancer who were admitted and gastrectomized in our Department of Surgery during July 1971 to March 1980. The control group consisted of 32 patients who were treated with mitomycin C and FT -207 during the first half of the period and the levamisole (LMS) group of 32 patients who were treated with the same regimen plus LMS during the latter half of the period. No significant statistical difference in their back ground factors was found. The LMS group was treated with 150 mg/day of LMS for 3 consecutive days every other week starting 3 days before operation. The follow-up study up to 30 postoperative months indicated an enhancing effect of LMS on the survival rate in patients with gastric cancer stage III undergoing curative resection. LMS proved to be effective on inhibition of the tumor growth when the tumor sizes ranged 4.0 to 7.9 cm, and the metastases were limited within the regional lymph node.
...
PMID:[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III]. 682 Aug 82

Despite surgical R0 resections, patients with gastric cancer stage UICC II-III have a high risk of recurrence and metachronic metastases. Preliminary evidence exists that adjuvant chemotherapy or neoadjuvant chemo(radio)therapy protocols may improve the prognosis of these patients undergoing surgery of gastric cancer with curative intention. As for palliative regimens, 5-fluorouracil and cisplatin are integral components of such (neo)adjuvant strategies. Upcoming cytostatic agents, i.e. irinotecan, docetaxel, oxaliplatin, and oral fluoropyridines are currently under investigation in new multimodality treatment regimens and may further increase R0 resection rates and may prolong disease-free and overall survival in the treatment of advanced localized gastric cancer.
...
PMID:(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? 1581 58